Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

rsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase II clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015   For the seventh year running, ... assess their overall digital maturity called the Multichannel ... companies are not maturing fast enough. While it,s true ... numerous ways overall and customers are increasingly "digital natives", ... digital customer engagement.  ...
(Date:6/26/2015)... Lawrence, MA (PRWEB) , ... June 26, 2015 ... ... the U.S. Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... referred to as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. ...
(Date:6/26/2015)... ... June 26, 2015 , ... DNA Genotek, ... of OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that it has awarded grants ... Gut Microbiome Grant Program. The company has awarded its OMNIgene®•GUT fecal/stool ...
(Date:6/25/2015)... 25, 2015 Current asthma medications, which ... or by dilating the airways, can stop working ... Brigham and Women,s Hospital and Harvard Medical School ... targeting certain sensory nerve endings in the lungs ... online in the journal Neuron on ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 2DNA Genotek Inc. Announces Recipients of Gut Microbiome Grant Program 3Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5
... in research funding, TORONTO, May 21 ... Thoracic Society (ATS), the world,s leading,professional organization for ... expansion of their research partnership in,pulmonary fibrosis. CPF ... awards for researchers in the United States pursuing ...
... Daiichi Sankyo Co., Ltd. announced today,that it has entered ... Pharma AG, a German biotechnology company focusing on research ... will purchase 100 percent of the stock and make ... for the,company. Closure of the transaction is subject to ...
... ALTO, Calif., May 20 Parents of children with,autism often ... do something to cause the disorder? Could it be genetic? ... there new medications or therapies that,might alleviate some of my ... teachers of children with,autism will have a unique opportunity to ...
Cached Biology Technology:Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 2Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010 3Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 2Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG 3First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 2First Annual Autism Conference at Packard Children's and Stanford Brings Parents and Researchers Together 3
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... This report analyzes the worldwide markets for ... Segments, which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay ... Systems, and Nephelometric Immunoassay Systems. The report provides separate ... , Japan , Europe ... Latin America , and Rest of World. Annual ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... span, prevent the spread of the disease, and is cost ... report in the February 10 issue of the New England ... of a two-paper series in NEJM on the value of ... used different data and methods than another study by VA, ...
... St Andrews have developed a new method of delivering ... which is cheap and powerful, could have important implications ... technology has huge potential for novel developments in the ... in this area. The new method -which involves a ...
... 1 million deaths worldwide every year and several research ... that result in the initiation and progression of these ... function of one gene, called Adenomatous Polyposis Coli (APC) ... innermost layer of the colon (called the epithelium) and ...
Cached Biology News:Boosting HIV screening can increase survival and is cost effective 2New methods of gene delivery using lasers 2Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer 2
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... The Model 111 mini IEF cell ... isoelectric focusing (IEF) using polyacrylamide or agarose ... chamber and lid, graphite electrodes, casting tray, ... support film for polyacrylamide, 5 sample templates, ...
... is the latest entry in the Biomek line. ... and increased robustness, it can meet the needs ... configured with either one or two pipetting pods. ... sets the standard for flexible laboratory solutions to ...
... By incorporating a wide range of next-generation ... sets a new standard for flexible laboratory ... handling including pipetting, dilution, dispensing, and ... thats as powerful and flexible as it ...
Biology Products: